Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx...

Descripción completa

Detalles Bibliográficos
Autores principales: Novotny, J. F., Cogswell, J., Inzunza, H., Harbison, C., Horak, C., Averbuch, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Industry Corner: Perspectives and Controversies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035792/
https://www.ncbi.nlm.nih.gov/pubmed/27502705
http://dx.doi.org/10.1093/annonc/mdw288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035792/
https://www.ncbi.nlm.nih.gov/pubmed/27502705
http://dx.doi.org/10.1093/annonc/mdw288

Ejemplares similares